Outset Medical’s Q2 2026: A Quiet Revenue Pulse with a Big Refresh Bet

Executive snapshot for OM: EPS considerations, revenue trajectory and the HCA boost

Outset Medical, Inc. (ticker: OM) delivered a second-quarter update that underscored a steady revenue base and a shifting margin mix, all while quietly lining up a meaningful contract with a national healthcare system. The release highlights the kind of earnings-story nuance that matters for EPS trajectory and the revenue forecast, even if the press sheet itself doesn’t publish an EPS figure in the excerpt. Analysts watching for an earnings surprise versus the EPS consensus will note the gross-margin improvement and the contribution from services, even as product revenue faced a YoY dip. The absence of a visible EPS read in this slice of the filing means the market will triangulate the story with cash flow, backlog, and the fresh HCA Healthcare deal.

What happened in the quarter

Revenue came in at $31.6 million for the quarter, up 1% year over year and up about 14% sequentially. Recurring revenue, mainly Tablo consumables and services, totaled $22.1 million, roughly flat versus the prior-year period. The mix shift toward services is notable given how it paves the way for steadier cash generation and potential leverage in margins over time.

Gross margin expanded to 42.0% from 37.8% a year earlier, with non-GAAP gross margin at 42.2%. Product gross profit was $10.1 million on a 46.1% gross margin, down from 48.9% in the prior year, while service and other gross profit stood at $3.2 million with a 32.6% margin, up from 6.9% a year ago. The overall margin improvement reflects a higher-margin services footprint and better mix even as product profitability softened slightly.

Operating expenses were $29.0 million, with R&D at $5.5 million and S&M at roughly $12.2 million. The company reported a net cash burn of about $9.5 million for the quarter, ending the period with roughly $151 million in cash, cash equivalents, and short-term investments plus restricted cash. In a notable strategic development, Outset signed a three-year, $40 million agreement with HCA Healthcare to refresh the existing fleet of Tablo systems across the nation’s largest health system, signaling a multi-year revenue opportunity and backlog visibility.

Management’s take and what it signals

In the press release, Leslie Trigg, Chair and CEO, framed the quarter as a validation of the company’s execution — the strongest pace of new site installations in years and early progress toward a refreshed backlog through the HCA deal. The deal appears to be a meaningful accelerant for revenue visibility and cross-selling opportunities within a large, multi-site health system. While this is a positive signal for revenue cadence, investors will want to watch whether this momentum translates into sustained margin expansion as service revenue scales and the product mix stabilizes.

Implications for Outset and sector peers

The Q2 results reinforce a thesis that, for Outset, the key is not only the top-line growth but a durable services engine. A 14% sequential revenue lift and a meaningful gross-margin lift suggest that the business is gaining leverage on its installed base and service offerings. The HCA deal, if representative of a broader push—refresh cycles and multi-year commitments—could redefine how the company converts installed capacity into recurring revenue and higher margins.

For sector peers, the signal is mixed: positive cash burn moderation, a clearer pathway to profitability through service revenue, and the potential for multi-year contracts that improve backlog visibility. Companies tied to dialysis and hospital-owned care platforms will be watching whether Outset’s mix shift is replicable and whether rivals can secure similarly sizable, long-duration refresh agreements that convert cycles into repeatable revenue streams.

Risks and what to monitor next

The absence of a disclosed EPS figure in this excerpt means analysts will focus on what the company reports in future releases to determine if there is a meaningful earnings surprise relative to consensus. Cash burn, while within a manageable range given the balance sheet, remains a headline risk if free cash flow does not improve as the services base grows. The durability of gross-margin gains will hinge on the trajectory of service revenue versus product revenue, as well as how well the company can scale R&D and selling expenses in support of a longer-term profitability plan.

What investors should watch for going forward

Key data points to track include EPS progression and any quarterly delta versus the EPS consensus, the trajectory of recurring revenue growth, and the pace of new site installations feeding the backlog. The HCA refresh agreement is a powerful datapoint for revenue visibility, but its success will depend on execution, term economics, and the company’s ability to expand within other large health systems. The revenue forecast for the rest of the year will be scrutinized in light of the service mix and the pace of product revenue recovery.

Bottom line

Outset Medical’s Q2 2026 results portray a company that is dialing in a more sustainable growth engine through its services and a strategic refresh deal with a major health system. The margin lift and cash position provide a cushion as it navigates a product mix rebalancing. For investors, the near-term question is whether the revenue cadence, powered by backlogged refreshes and recurring services, can translate into a clear path to EPS accretion and a convincing revenue forecast for the back half of the year. In the meantime, OM is quietly laying the groundwork for a prolonged, service-led trajectory—earnings season, take note.